Novo Nordisk Pharma Ltd. (Japan)

Alternate names: Novo Nordisk Pharma, Novo Nordisk Pharma Ltd., ノボノルディスクファーマ株式会社

ROR: 05gzvb546

OpenAlex ID: I4405265707

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

2022 · Takashi Kadowaki, Joakim Isendahl, et al. · The Lancet Diabetes & Endocrinology · 370

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

2020 · Yuichiro Yamada, Hideki Katagiri, et al. · The Lancet Diabetes & Endocrinology · 238

PDF

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

2018 · Kohei Kaku, Yuichiro Yamada, et al. · Diabetes Obesity and Metabolism · 136

PDF

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in J apanese people with type 2 diabetes

2017 · Yutaka Seino, Yasuo Terauchi, et al. · Diabetes Obesity and Metabolism · 132

PDF

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

2010 · Y. Seino, M.F. Rasmussen, et al. · Current Medical Research and Opinion · 118

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, P an‐ A sian, treat‐to‐target trial

2013 · Yukiko Onishi, Yasuhiko Iwamoto, et al. · Journal of Diabetes Investigation · 100

PDF

Clot retraction is mediated by factor XIII-dependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts

2013 · Kohji Kasahara, Mizuho Kaneda, et al. · Blood · 85

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

2015 · Yutaka Seino, Shizuka Kaneko, et al. · Journal of Diabetes Investigation · 61

PDF

Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial

2018 · John B. Buse, Anders L. Carlson, et al. · Diabetes Obesity and Metabolism · 57

PDF

Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment

2020 · Ataru Igarashi, Brian Bekker Hansen, et al. · Advances in Therapy · 52

PDF

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

2011 · Kohei Kaku, Mads Frederik Rasmussen, et al. · Journal of Diabetes Investigation · 49

PDF

2020 · Fumio Otsuka, Yutaka Takahashi, et al. · Clinical Endocrinology · 41

PDF

Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial

2025 · Ildiko Lingvay, Malik Benamar, et al. · Diabetologia · 38

PDF

Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial

2019 · Hirotaka Watada, Shizuka Kaneko, et al. · Diabetes Obesity and Metabolism · 37

PDF

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes

2022 · Shizuka Kaneko · touchREVIEWS in Endocrinology · 35

PDF

Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1‐year treat‐to‐target trial

2015 · M. Davies, T. Sasaki, et al. · Diabetes Obesity and Metabolism · 33

Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial

2011 · Yutaka Seino, Mads Frederik Rasmussen, et al. · Journal of Diabetes Investigation · 33

PDF

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

2018 · Ippei Ikushima, Lene Jensen, et al. · Advances in Therapy · 32

PDF

Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10‐year Japanese postmarketing surveillance data

2016 · K. Amano, I. Seita, et al. · Haemophilia · 32

PDF

Long-term efficacy and safety of two doses of Norditropin® (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients

2020 · Reiko Horikawa, Tsutomu Ogata, et al. · Endocrine Journal · 31

PDF

Perceptions, attitudes and barriers to obesity management: Japanese data from the ACTION‐IO study

2020 · Masato Iwabu, Toshimasa Yamauchi, et al. · Journal of Diabetes Investigation · 30

PDF

Ten‐year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan

2014 · H. Takedani, M. Shima, et al. · Haemophilia · 30

PDF

The Impact of Long-Term Growth Hormone Treatment on Metabolic Parameters in Japanese Patients with Short Stature Born Small for Gestational Age

2014 · Anne-Marie Kappelgaard, Fumiaki Kiyomi, et al. · Hormone Research in Paediatrics · 30

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial

2019 · Kohei Kaku, Eiichi Araki, et al. · Diabetes Obesity and Metabolism · 29

PDF

DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide ( IDegLira ) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin

2021 · Yu Pei, Bue R. Agner, et al. · Diabetes Obesity and Metabolism · 27

PDF

Works count: 176

Citation count: 3,910